GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

21

CRAFITY Score May Guide First-Line Therapy Selection in Unresectable HCC: Liver Cancer | June 2026

Atezolizumab plus bevacizumab remains the most widely used first-line therapy for unresectable hepatocellular carcinoma, while lenvatinib continues to be an important alternative. This international multicenter study evaluated whether...

22

PRISM Study: Real-World Outcomes of First-Line Systemic Therapy for Unresectable HCC: Liver Cancer | May 2026

PRISM is one of the largest prospective real-world studies evaluating systemic therapy for unresectable hepatocellular carcinoma in routine clinical practice across Japan. This analysis reports outcomes from the...

23

ARTE Score Predicts Decompensation on Atezo-Bev : J Hepatol | May 2026

Introduction: Introduction: Atezolizumab plus bevacizumab (Atezo-Bev) is the standard first-line systemic therapy for many patients with unresectable hepatocellular carcinoma (uHCC). However, treatment success depends not only on tumor...

24

Carbon-Ion Radiotherapy Matches Surgery in Early HCC : Hepatol Commun | June 2026

Introduction: Hepatocellular Carcinoma surgical resection remains a standard curative treatment for early-stage disease, but many patients are poor surgical candidates because of cirrhosis, portal hypertension, advanced age, or...

25

Immune-Related Adverse Events Strongly Predict Post-Transplant Rejection After Pretransplant Immunotherapy in HCC : Gut | May 2026

Introduction Hepatocellular Carcinoma management increasingly incorporates Immune Checkpoint Inhibitors for downstaging and bridging prior to Liver Transplantation. Although checkpoint inhibitors can successfully expand transplant eligibility and improve tumor...

26

Liver Transplantation Defines Long-Term Survival in HCC : Hepatol Commun | May 2026

Introduction Hepatocellular Carcinoma remains one of the leading causes of cancer-related mortality worldwide. Although curative-intent therapies such as liver transplantation, surgical resection and ablation can achieve durable disease...

27

IMbrave050 Update Questions Adjuvant Atezo-Bev in HCC : J Hepatol | May 2026

Introduction Recurrence after curative-intent resection or ablation remains one of the greatest challenges in Hepatocellular Carcinoma management, with early relapse rates remaining high even after apparently successful treatment....

28

EBRT Achieves Competitive Survival in Early HCC : J Clin Oncol | May 2026

Introduction External Beam Radiation Therapy has historically played a limited role in the management of Hepatocellular Carcinoma because of concerns regarding radiation-induced liver injury and limited survival data....

29

Precision Genomics in Refractory PLC : J Hepatol | May 2026

Introduction Advanced Hepatocellular Carcinoma, Cholangiocarcinoma and rare primary liver cancers remain therapeutically challenging after progression on standard systemic therapy. Conventional targeted next-generation sequencing panels identify actionable alterations in...

30

Liver Function Dominates Risk Prediction After HCC Locoregional Therapy : Liver Transpl | May 2026

Introduction Locoregional therapy (LRT) remains a cornerstone treatment strategy for patients with early- and intermediate-stage Hepatocellular Carcinoma. Although procedures such as transarterial chemoembolization and ablative therapies are routinely...

Previous
12348
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer